MX2011012659A - Terapia con vacunas para neovascularizacion coroidea. - Google Patents

Terapia con vacunas para neovascularizacion coroidea.

Info

Publication number
MX2011012659A
MX2011012659A MX2011012659A MX2011012659A MX2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A MX 2011012659 A MX2011012659 A MX 2011012659A
Authority
MX
Mexico
Prior art keywords
neovascularization
choroidal neovascularization
vaccine therapy
vegfr
peptide
Prior art date
Application number
MX2011012659A
Other languages
English (en)
Inventor
Yusuke Nakamura
Takuya Tsunoda
Motokazu Tsujikawa
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of MX2011012659A publication Critical patent/MX2011012659A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B60—VEHICLES IN GENERAL
    • B60N—SEATS SPECIALLY ADAPTED FOR VEHICLES; VEHICLE PASSENGER ACCOMMODATION NOT OTHERWISE PROVIDED FOR
    • B60N2/00—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles
    • B60N2/02—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable
    • B60N2/22—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable
    • B60N2/225—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms
    • B60N2/2252—Seats specially adapted for vehicles; Arrangement or mounting of seats in vehicles the seat or part thereof being movable, e.g. adjustable the back-rest being adjustable by cycloidal or planetary mechanisms in which the central axis of the gearing lies inside the periphery of an orbital gear, e.g. one gear without sun gear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Mechanical Engineering (AREA)
  • Transportation (AREA)
  • Aviation & Aerospace Engineering (AREA)
  • Ophthalmology & Optometry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona agentes y métodos farmacéuticos novedosos para tratar o prevenir enfermedades causadas por la neovascularización en la coroides (maculopatía neovascular). La presente invención proporciona composiciones farmacéuticas y vacunas para tratar y/o prevenir enfermedades causadas por la neovascularización en la coroides (maculopatía neovascular), que comprende por lo menos un tipo de cada uno de un péptido que comprende una secuencia de aminoácidos derivada de una proteína VEGFR-1 y que tiene una actividad de inducción de células T citotóxicas, y un péptido que comprende una secuencia de aminoácidos derivada de una proteína VEGFR-2 y que tiene una actividad de inducción de células T citotóxicas.
MX2011012659A 2009-06-11 2010-06-10 Terapia con vacunas para neovascularizacion coroidea. MX2011012659A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009140363 2009-06-11
PCT/JP2010/003871 WO2010143435A1 (en) 2009-06-11 2010-06-10 Vaccine therapy for choroidal neovascularization

Publications (1)

Publication Number Publication Date
MX2011012659A true MX2011012659A (es) 2011-12-16

Family

ID=43308696

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012659A MX2011012659A (es) 2009-06-11 2010-06-10 Terapia con vacunas para neovascularizacion coroidea.

Country Status (14)

Country Link
US (1) US8975229B2 (es)
EP (1) EP2440226A4 (es)
JP (1) JP5688587B2 (es)
KR (1) KR20120038419A (es)
CN (1) CN102802654A (es)
AU (1) AU2010259797B2 (es)
BR (1) BRPI1013025A2 (es)
CA (1) CA2764562A1 (es)
IL (1) IL216402A0 (es)
MX (1) MX2011012659A (es)
RU (1) RU2555345C2 (es)
SG (2) SG10201403109VA (es)
TW (1) TW201109029A (es)
WO (1) WO2010143435A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2095822T3 (da) 2005-02-28 2014-01-13 Oncotherapy Science Inc Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
CA2678432A1 (en) * 2007-02-16 2008-08-21 Oncotherapy Science, Inc. Vaccine therapy for choroidal neovascularization
FR2990352A1 (fr) 2012-05-10 2013-11-15 Univ Paris 13 Composition immunogene comprenant un peptide derive du vegf et ses utilisations
CN110612115A (zh) * 2017-05-19 2019-12-24 学校法人庆应义塾 针对脑神经疾病的肽疫苗和肽疫苗组合物

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861301A (en) 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
CN1701814A (zh) 1992-11-13 2005-11-30 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k－1
EP0694042B1 (en) 1993-03-25 2004-11-03 Merck & Co. Inc. Inhibitor of vascular endothelial cell growth factor
US6100071A (en) 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
US6080728A (en) 1996-07-16 2000-06-27 Mixson; A. James Carrier: DNA complexes containing DNA encoding anti-angiogenic peptides and their use in gene therapy
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998031794A1 (fr) 1997-01-17 1998-07-23 Toa Gosei Co., Ltd. Polypeptide liant le facteur vegf
JP4405597B2 (ja) 1997-06-18 2010-01-27 メルク エンド カムパニー インコーポレーテッド ヒト受容体型チロシンキナーゼｋｄｒ
WO1999040118A1 (fr) 1998-02-04 1999-08-12 Kyowa Hakko Kogyo Co., Ltd. Anticorps diriges contre le recepteur kdr humain du vegf
GB9804121D0 (en) 1998-02-26 1998-04-22 Cancer Res Campaign Tech Anti-angiogenic vaccines: materials and methods relating thereto
AU3850299A (en) 1998-05-20 1999-12-06 Kyowa Hakko Kogyo Co. Ltd. Vegf activity inhibitors
WO2001012809A2 (en) 1999-08-13 2001-02-22 Crucell Holland B.V. Heterodimeric vegf variants used for inhibiting angiogenesis
US7264810B2 (en) 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
WO2003028643A2 (en) 2001-10-01 2003-04-10 Targesome, Inc. Targeted therapeutic lipid constructs having cell surface targets
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
EP2267021B1 (en) 2002-09-12 2015-02-18 Oncotherapy Science, Inc. KDR peptides and vaccines comprising the same
CA2498191C (en) 2002-09-18 2012-04-10 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
CN1926551B (zh) 2003-10-27 2010-06-16 罗斯塔生化科技有限责任公司 用于基因沉默的siRNA的设计方法
JP2006215988A (ja) * 2005-02-07 2006-08-17 Ntt Docomo Kansai Inc 認証システム、携帯端末装置及び認証方法
DK2095822T3 (da) 2005-02-28 2014-01-13 Oncotherapy Science Inc Epitoppeptider afledt af karendothelvækstfaktorreceptor-1 samt vacciner indeholdende disse peptider
US20060234941A1 (en) * 2005-04-15 2006-10-19 The Gov. Of The Usa As Represented By The Secretary Of The Dept. Of Health & Human Services Peptide epitopes of VEGFR-2/KDR that inhibit angiogenesis
JP2006315988A (ja) 2005-05-11 2006-11-24 Mototake Shimizu ケモカイン産生誘導効果を有する血管新生阻害物質
CA2678432A1 (en) * 2007-02-16 2008-08-21 Oncotherapy Science, Inc. Vaccine therapy for choroidal neovascularization
EP2171082B1 (en) 2007-06-14 2012-11-28 Oncotherapy Science, Inc. Methods of identifying agents that modulate methylation of vegfr1 by smyd3
TWI436775B (zh) * 2007-08-24 2014-05-11 Oncotherapy Science Inc 以抗原胜肽合併化療藥劑治療胰臟癌

Also Published As

Publication number Publication date
EP2440226A1 (en) 2012-04-18
IL216402A0 (en) 2012-01-31
BRPI1013025A2 (pt) 2016-04-05
WO2010143435A1 (en) 2010-12-16
US8975229B2 (en) 2015-03-10
AU2010259797B2 (en) 2015-06-25
CN102802654A (zh) 2012-11-28
SG176737A1 (en) 2012-01-30
JP2012529423A (ja) 2012-11-22
JP5688587B2 (ja) 2015-03-25
CA2764562A1 (en) 2010-12-16
US20120156233A1 (en) 2012-06-21
RU2012100241A (ru) 2013-07-20
AU2010259797A1 (en) 2011-12-08
KR20120038419A (ko) 2012-04-23
TW201109029A (en) 2011-03-16
RU2555345C2 (ru) 2015-07-10
EP2440226A4 (en) 2013-09-18
SG10201403109VA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
MX2016002152A (es) Metodo para aumentar la expresion de proteinas codificadas por arn.
MX350501B (es) Nanotecnologia de vacuna.
MX2019012884A (es) Terapia de combinacion.
MX359516B (es) Composiciones y metodos para prevenir o tratar enfermedades, afecciones, o procesos caracterizados por la proliferacion abrellante de fibro blasto y deposicion de matriz extracelular.
EP2949344A3 (en) Use of intracellular enzymes for the release of covalently linked bioactives
MX2017000080A (es) Conjugados y particulas direccionados y formulaciones de estos.
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
EA201490994A1 (ru) Функционально-модифицированные олигонуклеотиды и их субъединицы
MX2014002171A (es) Tratamientos de combinacion para hepatitis c.
NZ600544A (en) Compositions and methods for the treatment of angiogenesis-related eye diseases
BR112015010396A2 (pt) terapia de combinação
JO3122B1 (ar) مشتقات إسترا-5،3،1(10)، 16- تترايين-3- كربوكساميد، عمليات لتحضيرها، مستحضرات دوائية تشتمل عليها واستخدامها لتحضير أدوية
MX363822B (es) Formulaciones de liposomas.
MX2017000448A (es) Uso terapeutico de proteinas morfogeneticas oseas.
MX2011012659A (es) Terapia con vacunas para neovascularizacion coroidea.
EA201591108A1 (ru) Слитый гормон роста человека и альбумин, составы и их применения
WO2015140172A3 (en) A medicament for use in a method of inducing or extending a cellular cytotoxic immune response
NZ601980A (en) Recombinant proteins for use in vaccine, antibodies against said proteins, and diagnostic and therapeutic methods including the same
IN2014DN09240A (es)
CA2755897A1 (en) Treatment of cancers with immunostimulatory hiv tat derivative polypeptides
MX360658B (es) Uso de factor antisecretorio (fa) en el tratamiento de un glioblastoma.
BR112015013215A2 (pt) proteína slurp-1 para uso na fabricação de medicamentos para o tratamento de doenças oculares
MX362485B (es) Nuevos inhibidores de rock.
MX2009008750A (es) Terapia de vacuna para neovascularizacion coroidal.
MX2019007906A (es) Composicion vacunal que comprende un mutante de la interleucina-15 humana.

Legal Events

Date Code Title Description
FG Grant or registration